TD Waterhouse Canada’s Eupraxia Pharmaceuticals EPRX Stock Holding History

TD Waterhouse Canada’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$535K	Sell	79,607 -2,118	-3%	-$14.6K	﹤0.01%	860
2026 Q1	$590K	Buy	81,725 +72,125	+751%	+$581K	﹤0.01%	810
2025 Q4	$71.7K	Hold	9,600	–	–	﹤0.01%	1120
2025 Q3	$56.2K	Hold	9,600	–	–	﹤0.01%	1166
2025 Q2	$55.9K	Sell	9,600 -95,386	-91%	-$366K	﹤0.01%	1099
2025 Q1	$343K	Buy	+104,986	New	+$362K	﹤0.01%	708
2024 Q4	–	Sell	-1,500	Closed	-$3.83K	–	2068
2024 Q3	$3.83K	Buy	+1,500	New	+$3.94K	﹤0.01%	1544

Other funds holding EPRX

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

TWA

TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

TD Waterhouse Canada's EPRX Position: Q2 2026 in Review

TD Waterhouse Canada reduced its Eupraxia Pharmaceuticals (EPRX) stake by 2.6% in Q2 2026, selling an estimated $14.6K and leaving 79,607 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #860.

TD Waterhouse Canada first reported a position in EPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $590K in Q1 2026. 3 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

TD Waterhouse Canada held 79,607 shares of Eupraxia Pharmaceuticals worth $535K as of Q2 2026.
TD Waterhouse Canada sold 2,118 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $14.6K.
Eupraxia Pharmaceuticals made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #860 holding.
TD Waterhouse Canada first reported a position in Eupraxia Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
TD Waterhouse Canada's Eupraxia Pharmaceuticals position peaked at $590K in Q1 2026.
3 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.